Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Minimal residual disease (MRD) is a key indicator of treatment response quality in both acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).
• The clinical implementation of MRD monitoring for guiding therapy has progressed significantly faster in ALL compared to AML.
• Pediatric ALL has been particularly rapid in adopting MRD-guided treatment strategies.

Purpose of the Study:

• To examine the reasons behind the differential adoption rates of MRD monitoring in ALL versus AML.
• To discuss the factors contributing to ALL's greater amenability to MRD-based risk stratification and remission redefinition.
• To provide perspective on the future integration of MRD in AML treatment paradigms.

Main Methods:

• Comparative analysis of MRD implementation in ALL and AML clinical practice.
• Review of current literature and guidelines regarding MRD monitoring.
• Discussion of biological and clinical factors influencing MRD measurement and utility.

Main Results:

• ALL, particularly pediatric ALL, has established robust MRD assays and integrated them into treatment protocols more readily than AML.
• Differences in disease biology, treatment intensity, and clinical trial infrastructure may explain the faster adoption in ALL.
• The concept of MRD-guided risk allocation and revised complete remission definitions is more established in ALL.

Conclusions:

• The rapid integration of MRD in ALL highlights its potential for personalized therapy and improved outcomes.
• Further research and standardization are needed to accelerate MRD implementation in AML.
• Understanding the barriers and facilitators in ALL can inform strategies to enhance MRD use in AML for better patient management.